CareDx: Peter Maag, Reginald Seeto
CareDx announced that current Chairman and CEO Peter Maag will assume the role of executive chairman of the board, effective Nov. 1, and that current President and Chief Business Officer (CBO) Reginald Seeto will then assume the role of president and CEO. Seeto will also join the company's board.
Maag joined CareDx in 2012 as CEO and led the company through its IPO. Seeto joined CareDx in 2018 as president and CBO, leading the company's commercial, clinical, manufacturing, and R&D organizations.
Qiagen: Jean-Pascal Viola
Qiagen has appointed Jean-Pascal Viola as senior vice president, head of the molecular diagnostics business area, in addition to his current role as leader of corporate business development and intellectual property and litigation, which he assumed in 2015. Viola will also continue to serve as a member of Qiagen's executive committee. He joined Qiagen in 2005 and has held various roles in Singapore, the US, and Germany. Since joining the business development team in 2007, he played a leading role in the acquisitions of Cellestis, Stat-Dx, NeuMoDx, and the assets of Forumlatrix related to digital PCR.
Inscripta: Sri Kosaraju
Inscripta has appointed Sri Kosaraju as its new president and CEO. Kosaraju succeeds Kevin Ness, who was the company's CEO since 2016, and who will remain as an advisor.
Kosaraju currently serves on the board of directors and is the chair of the audit committee of 10x Genomics. He also serves on the board of the nonprofit Testing for America. Prior to joining Inscripta, Kosaraju was president of Penumbra, and spent 16 years at JP Morgan, where he most recently served as head of Healthcare Equity Capital Markets and co-head of Technology Equity Capital Markets.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.